Ansell Limited
Ansell makes surgical, industrial, and cleanroom gloves and PPE sold worldwide under regulatory clearances.
On the record
Checkpoint: Ansell FY26 full-year results, testing whether organic growth returns to positive territory
The call
Ansell holds ground in regulated, spec-in glove and PPE segments while commodity nitrile pricing from Malaysian rivals keeps overall growth flat.
Ansell is a 130-year-old company that makes medical gloves, surgical gloves, and protective equipment sold mainly to hospitals and factories. It has real advantages in the regulated medical segments because hospitals and cleanrooms have strict rules about which suppliers they can buy from, and getting those approvals takes years and money, which makes it hard for new companies to break in. However, Ansell faces strong price competition from Malaysian glove makers like Top Glove and Hartalega, which copy its basic products and sell them cheaper, and the company is also dealing with flat sales growth right now and new leadership. The key thing to watch is whether the new CEO can get sales growing again and whether hospitals and buyers stay willing to pay more for Ansell's brand instead of switching to cheaper brands when costs are tight.
Why
01
AI pressure: None apparent. Gloves and PPE are physical, regulated products; no AI product replaces the manufacturing, testing, or clearance work Ansell does. Could AI do the core job? Unlikely.
02
Bigger players: Top Glove, Hartalega, Kossan, and Supermax (Malaysia, commodity nitrile gloves). Malaysian makers undercut Ansell on price in commodity disposable gloves, pressuring the low end while Ansell leans on higher-spec segments. Could a giant copy it? Probably.
03
What protects it. FDA clearances and hospital/cleanroom spec-in procurement make surgical and industrial customers slow to switch suppliers.
What would change this call
Ansell's FY26 full-year results (~23 Aug 2026) show organic revenue growth. Positive low single-digit growth would show the moat held; another negative half signals commodity pressure is winning.
Malaysian rivals announce FDA clearances or hospital-system contracts in surgical/cleanroom gloves. Would show commodity players moving up-market into Ansell's protected regulated segments.
Ansell's gross margin trend in FY26 H2 versus H1 FY26. Margin compression alongside flat sales would confirm pricing power is eroding, not just volume.
Malaysian rivals announce FDA clearances or hospital-system contracts in surgical/cleanroom gloves. Would show commodity players moving up-market into Ansell's protected regulated segments.
Ansell's gross margin trend in FY26 H2 versus H1 FY26. Margin compression alongside flat sales would confirm pricing power is eroding, not just volume.
Key numbers
- FY25 revenue US$2.0bn, up 23.7% y/y
- H1 FY26 organic growth: -0.6%
- US$200m buyback announced after 33% profit rise
Named risks
- Unresolved 2023 shareholder class action alleging misleading EPS guidance disclosure.
- US tariff policy volatility (Section 232/301) despite Feb 2026 Supreme Court reciprocal-tariff ruling.
- Negative organic revenue growth (-0.6%) in H1 FY26 amid subdued end markets.
- New CEO transition (Feb 2026) during ongoing KBU integration and soft demand.
- Commodity glove price competition from Malaysian rivals pressuring Industrial segment.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Top Glove | contesting | Malaysian commodity nitrile glove price competition, ongoing through H1 FY26 (Dec 2025) |
| Hartalega Holdings | contesting | Disposable glove price competition; Ansell organic sales flat/-0.6% H1 FY26 |
| Kossan Rubber Industries | contesting | Commodity glove manufacturing rival named in 2024 industry report |
| Supermax Corporation | contesting | Malaysian glove maker competing on price as of 2025 PPE evaluation report |
| Kimberly-Clark Professional | gaining on | Ansell acquired KC's PPE business for ~US$635m, completed 2 July 2024 |
| 3M, Honeywell, DuPont | contesting | Diversified PPE giants coexist in regulated surgical/cleanroom segments as of 2026 |
Questions people ask
- What is the biggest risk to Ansell?
- The main pressure comes from Malaysian commodity glove makers Top Glove, Hartalega, and Supermax, who compete hard on price in the lower-value glove segment and are pushing up-market into Ansell's specialty business. Ansell's organic growth of just 0.7% in FY26 first half (as of 2025-12-31) suggests even the specialty side is only inching forward under this pressure. A second watch-item is the securities class action filed in August 2023, which is a legal matter worth tracking toward resolution by 2026-12-31.
- Is Ansell in financial trouble?
- No signs of financial trouble stand out. FY25 revenue was US$2,003.3m with adjusted EPS of 126.1 US cents for the year ended 2025-06-30, and net debt to EBITDA improved to 1.5x as of 2025-12-31. Growth is slow, with organic growth of only 0.7% in FY26 first half, but this reflects a maturity issue rather than a solvency one.
- Who are Ansell's biggest competitors?
- Ansell competes against Malaysian commodity glove producers Top Glove, Hartalega, and Supermax on price, and against diversified safety giants 3M and Honeywell on bundled enterprise portfolios. In hospital PPE contracts it also faces Molnlycke, Medline, and Cardinal Health, while Kimberly-Clark Professional is emerging with newer sensor-glove technology as of the July 2026 assessment.
- Is Ansell at risk from AI?
- AI threat is rated not-applicable for Ansell. Its products are physical gloves and safety gear worn on hands, not software, so no AI product can replace the item itself, according to the July 2026 assessment.
- How strong is Ansell's competitive moat?
- Ansell's moat rests on certifications, regulatory approvals, and embedded hospital-system contracts that make switching costly for buyers, giving it a durable position among safety-equipment suppliers. That said, the moat has not translated into fast growth: FY26 first-half organic growth was just 0.7% as of 2025-12-31, and net debt to EBITDA stood at 1.5x, reflecting a business defending its position more than expanding it.
- What should I watch next for Ansell?
- Two dated items are worth tracking. First, Ansell's FY26 full-year results due 25 August 2026 will show whether organic growth moves past the 1% mark and whether new CEO Nathalie Ahlstrom's growth push is gaining traction. Second, the securities class action filed in August 2023 is a legal matter to follow toward a settlement or judgment by 2026-12-31.
Timeline
- 2026-07-23Jefferies cuts Ansell price target 1.5% to A$38.20 per share
- 2026-02-20US Supreme Court strikes down IEEPA-based reciprocal tariffs affecting Ansell cost base
- 2026-02-16Nathalie Ahlström becomes CEO, succeeding Neil Salmon; H1 FY26 results released
- 2025-12-31H1 FY26 ends: revenue US$1,026.6m, organic sales down 0.6%
- 2025-11-03Ansell acquires controlling stake in Global Industrial Hub
- 2025-08-24FY25 results: sales up 23.7% to US$2,003.3m; US$200m buyback announced
- 2024-07-02Ansell completes ~US$635m acquisition of Kimberly-Clark's PPE business (KBU)
- 2024-05-14Ansell announces Kimberly-Clark PPE business acquisition
- 2023-08-09Slater and Gordon files shareholder class action against Ansell
Head to head
Revision history
30 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Ansell (2026-07-30)
- Business Structure, Industry & Snapshot
- gurufocus.com (2026-07-30)
- Ansell announces the acquisition of Kimberly-Clark's PPE Business (2024-05-14)
- Half Year Financial Report
- Ansell Limited Annual Report 2025
- FY25 Full Year Results (2025-08-25)
- Ansell FY26 Half Year Results (2026-02-16)
- Ansell (ANN) Revenue (2026-06-23)
- Ansell Announces $200M Buyback as Price Rises Offset Tariffs (2025-08-24)
- Ansell Annual Report - Interactive Summary
- Ansell Limited - Company Profile Report